Cargando…

Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study

Merkel cell carcinoma (MCC) is a rare cutaneous carcinoma that has gained enormous interest since the discovery of Merkel cell polyoma virus, which is a causative oncogenic agent in the majority of MCC tumours. Increased research has focused on effective treatment options with immuno-oncology. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahi, Helka, Their, Jenny, Gissler, Mika, Koljonen, Virve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281542/
https://www.ncbi.nlm.nih.gov/pubmed/32414207
http://dx.doi.org/10.3390/cancers12051224
_version_ 1783543944782544896
author Sahi, Helka
Their, Jenny
Gissler, Mika
Koljonen, Virve
author_facet Sahi, Helka
Their, Jenny
Gissler, Mika
Koljonen, Virve
author_sort Sahi, Helka
collection PubMed
description Merkel cell carcinoma (MCC) is a rare cutaneous carcinoma that has gained enormous interest since the discovery of Merkel cell polyoma virus, which is a causative oncogenic agent in the majority of MCC tumours. Increased research has focused on effective treatment options with immuno-oncology. In this study, we reviewed the real-world data on different treatments given to MCC patients in Finland in 1986–2016. We used the Finnish Cancer Registry database to find MCC patients and the Hospital Discharge Register and the Cause-of-Death Register to obtain treatment data. We identified 376 MCC patients and 33 different treatment entities and/or combinations of treatment. An increase was noted in the incidence of MCC since 2005. Therefore, the cohort was divided into two groups: the “early“ group with time of diagnosis between years 1986 and 2004 and the “late” group with time of diagnosis between 2005 and 2016. The multitude of different treatment combinations is a relatively new phenomenon; before the year 2005, only 11 treatments or treatment combinations were used for MCC patients. Our data show that combining radiation therapy with simple excision provided a survival advantage, which was, however, lost after adjustment for stage or age. Our registry study serves as a baseline treatment efficacy comparison as we move into the age of immunotherapy in MCC. Standardizing the treatment of MCC patients in Finland requires more work on awareness and multidisciplinary co-operation.
format Online
Article
Text
id pubmed-7281542
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72815422020-06-17 Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study Sahi, Helka Their, Jenny Gissler, Mika Koljonen, Virve Cancers (Basel) Article Merkel cell carcinoma (MCC) is a rare cutaneous carcinoma that has gained enormous interest since the discovery of Merkel cell polyoma virus, which is a causative oncogenic agent in the majority of MCC tumours. Increased research has focused on effective treatment options with immuno-oncology. In this study, we reviewed the real-world data on different treatments given to MCC patients in Finland in 1986–2016. We used the Finnish Cancer Registry database to find MCC patients and the Hospital Discharge Register and the Cause-of-Death Register to obtain treatment data. We identified 376 MCC patients and 33 different treatment entities and/or combinations of treatment. An increase was noted in the incidence of MCC since 2005. Therefore, the cohort was divided into two groups: the “early“ group with time of diagnosis between years 1986 and 2004 and the “late” group with time of diagnosis between 2005 and 2016. The multitude of different treatment combinations is a relatively new phenomenon; before the year 2005, only 11 treatments or treatment combinations were used for MCC patients. Our data show that combining radiation therapy with simple excision provided a survival advantage, which was, however, lost after adjustment for stage or age. Our registry study serves as a baseline treatment efficacy comparison as we move into the age of immunotherapy in MCC. Standardizing the treatment of MCC patients in Finland requires more work on awareness and multidisciplinary co-operation. MDPI 2020-05-13 /pmc/articles/PMC7281542/ /pubmed/32414207 http://dx.doi.org/10.3390/cancers12051224 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sahi, Helka
Their, Jenny
Gissler, Mika
Koljonen, Virve
Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study
title Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study
title_full Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study
title_fullStr Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study
title_full_unstemmed Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study
title_short Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study
title_sort merkel cell carcinoma treatment in finland in 1986–2016—a real-world data study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281542/
https://www.ncbi.nlm.nih.gov/pubmed/32414207
http://dx.doi.org/10.3390/cancers12051224
work_keys_str_mv AT sahihelka merkelcellcarcinomatreatmentinfinlandin19862016arealworlddatastudy
AT theirjenny merkelcellcarcinomatreatmentinfinlandin19862016arealworlddatastudy
AT gisslermika merkelcellcarcinomatreatmentinfinlandin19862016arealworlddatastudy
AT koljonenvirve merkelcellcarcinomatreatmentinfinlandin19862016arealworlddatastudy